CSL
ASX:CSL Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 114 Fair Values set on narratives written by author
WA
Consensus Narrative from 16 Analysts
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
Key Takeaways Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings. Product rollouts and expanded market approvals, especially in HAE therapy, aim to drive revenue growth and offset vaccine sector challenges.
View narrativeAU$315.99
FV
16.9% undervalued intrinsic discount6.96%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
1 day ago author updated this narrative